HCV FUSION POLYPEPTIDEDS
    31.
    发明申请
    HCV FUSION POLYPEPTIDEDS 有权
    HCV融合多肽

    公开(公告)号:US20100092503A1

    公开(公告)日:2010-04-15

    申请号:US12310406

    申请日:2007-02-27

    摘要: The invention provides HCV fusion polypeptides including truncated or full-length HCV NS5 polypeptides, and a portion of the HCV NS2 polypeptide, fused to at least one other HCV epitope derived from another region of the HCV polyprotein. The fusions can be used in methods of stimulating an immune response to HCV, for example a cellular immune response to HCV, such as activating hepatitis C virus (HCV)-specific T cells, including CD4+ and CD8+ T cells. The method can be used in model systems to develop HCV-specific immunogenic compositions, as well as to immunize against HCV.

    摘要翻译: 本发明提供了HCV融合多肽,其包括截短的或全长的HCV NS5多肽,以及HCV NS2多肽的一部分,其与至少一种源自HCV多蛋白的另一区域的其它HCV表位融合。 融合物可以用于刺激对HCV的免疫应答的方法,例如对HCV的细胞免疫应答,例如激活丙型肝炎病毒(HCV)特异性T细胞,包括CD4 +和CD8 + T细胞。 该方法可以在模型系统中用于开发HCV特异性免疫原性组合物,以及免疫HCV。

    Truncated hepatitis C virus NS5 domain and fusion proteins comprising same
    32.
    发明申请
    Truncated hepatitis C virus NS5 domain and fusion proteins comprising same 审中-公开
    截短的丙型肝炎病毒NS5结构域和包含其的融合蛋白

    公开(公告)号:US20060088819A1

    公开(公告)日:2006-04-27

    申请号:US11131901

    申请日:2005-05-17

    摘要: The invention provides truncated HCV NS5 polypeptides and fusion proteins comprising the truncated NS5 polypeptides, fused to at least one other HCV epitope derived from another region of the HCV polyprotein. The fusions can be used in methods of stimulating an immune response to HCV, for example a cellular immune response to HCV, such as activating hepatitis C virus (HCV)-specific T cells, including CD4+ and CD8+ T cells. The method can be used in model systems to develop HCV-specific immunogenic compositions, as well as to immunize a mammal against HCV.

    摘要翻译: 本发明提供了截短的HCV NS5多肽和包含截短的NS5多肽的融合蛋白,其融合至至少一种源自HCV多蛋白的另一区域的其它HCV表位。 融合物可以用于刺激对HCV的免疫应答的方法,例如对HCV的细胞免疫应答,例如活化丙型肝炎病毒(HCV)特异性T细胞,包括CD4 +和CD8 + T细胞。 该方法可以在模型系统中用于开发HCV特异性免疫原性组合物,以及免疫哺乳动物抗HCV。

    Expressing hepatitis B virus surface antigen for vaccine preparation
    39.
    发明申请
    Expressing hepatitis B virus surface antigen for vaccine preparation 有权
    表达用于疫苗制备的乙型肝炎病毒表面抗原

    公开(公告)号:US20090175904A1

    公开(公告)日:2009-07-09

    申请号:US11918864

    申请日:2006-04-14

    摘要: HBsAg is expressed in a Saccharomyces cerevisiae host, carrying a plasmid having a HBsAg coding sequence, wherein the plasmid includes: (1) an upstream promoter from a glyceraldehyde-3-phosphate dehydrogenase gene, for controlling expression of the HBsAg coding sequence; and (2) an ARG3 transcription terminator downstream of the HBsAg coding sequence. The plasmids may also include: (3) a LEU2 selection marker; (4) a 2μ plasmid sequence; and (5) an origin of replication functional in Escherichia coli. HBsAg can be expressed in this host, and can be purified for use in the manufacture of vaccines, and in particular for the manufacture of combination vaccines and in new monovalent HBV vaccines e.g. with non-alum adjuvants.

    摘要翻译: HBsAg在酿酒酵母宿主中表达,携带具有HBsAg编码序列的质粒,其中质粒包括:(1)用于控制HBsAg编码序列表达的甘油醛-3-磷酸脱氢酶基因的上游启动子; 和(2)HBsAg编码序列下游的ARG3转录终止子。 质粒还可以包括:(3)LEU2选择标记; (4)2mu质粒序列; 和(5)在大肠杆菌中起作用的复制起点。 HBsAg可以在该宿主中表达,并且可以纯化用于制造疫苗,特别是用于制造组合疫苗和新的单价HBV疫苗例如抗体。 与非明矾佐剂。